Epstein-Barr Virus: Competitive Landscape

• In 2024, more than 700 million people are at risk of EBV infection in the 16 countries covered in the analyst’s epidemiology forecast.
• Currently, only one approved product available in the therapeutic market space for EBV and none of the vaccine is currently approved for EBV prophylaxis.
• R&D activities for EBV are moderate with 43 molecules in the pipeline, of which only one drug is in Phase III and eight drugs are in Phase II.
• Over the past 10 years, the US has hosted the highest number of trial sites for EBV, at more than 650 trial sites.
• During the past decade, partnerships and licensing agreements were the most prominent deal types in North America and Europe.

Scope

Components of the report include :

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Epstein-Barr Virus market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Epstein-Barr Virus market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.